PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16775175-0 2006 Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer. Raloxifene Hydrochloride 11-21 prolactin Homo sapiens 37-46 17054466-12 2006 CONCLUSIONS: Our study demonstrates for the first time that raloxifene and clomiphene affect the secretion of PRL in postmenopausal women in a similar manner. Raloxifene Hydrochloride 60-70 prolactin Homo sapiens 110-113 16775175-2 2006 Estrogen is a significant positive regulator of prolactin synthesis; therefore, raloxifene, a selective estrogen receptor modulator under study as a breast cancer prevention agent, may modulate both estradiol and prolactin levels by inhibiting estradiol from binding to its receptor. Raloxifene Hydrochloride 80-90 prolactin Homo sapiens 48-57 16775175-2 2006 Estrogen is a significant positive regulator of prolactin synthesis; therefore, raloxifene, a selective estrogen receptor modulator under study as a breast cancer prevention agent, may modulate both estradiol and prolactin levels by inhibiting estradiol from binding to its receptor. Raloxifene Hydrochloride 80-90 prolactin Homo sapiens 213-222 16775175-8 2006 CONCLUSIONS: This report is the first to examine the long-term effects of raloxifene on prolactin, estradiol, and SHBG levels in premenopausal women who are also at increased risk for developing invasive breast cancer. Raloxifene Hydrochloride 74-84 prolactin Homo sapiens 88-97 15146102-0 2004 Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women. Raloxifene Hydrochloride 11-21 prolactin Homo sapiens 102-111 15146102-6 2004 The prolactin level decreased in the raloxifene group but not in the CCEP group (-17.0%; p < 0.001 vs +13.3%, p = no significance; NS). Raloxifene Hydrochloride 37-47 prolactin Homo sapiens 4-13 15146102-7 2004 Consequently, long-term administration of raloxifene up to 1 yr decreases serum prolactin level significantly and may be a therapeutic alternative for postmenopausal osteoporotic women with hyperprolactinemia. Raloxifene Hydrochloride 42-52 prolactin Homo sapiens 80-89 12370106-0 2002 Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women. Raloxifene Hydrochloride 24-34 prolactin Homo sapiens 54-63 12370106-1 2002 OBJECTIVE: To evaluate the effects of a 6 month administration of raloxifene hydrochloride, a selective estrogen receptor modulator which was recently approved for the prevention of osteoporosis, on serum gonadotropin and prolactin (PRL) levels and on TRH-stimulated PRL responsiveness in postmenopausal women who have not undergone estrogen replacement therapy. Raloxifene Hydrochloride 66-90 prolactin Homo sapiens 222-231 12370106-1 2002 OBJECTIVE: To evaluate the effects of a 6 month administration of raloxifene hydrochloride, a selective estrogen receptor modulator which was recently approved for the prevention of osteoporosis, on serum gonadotropin and prolactin (PRL) levels and on TRH-stimulated PRL responsiveness in postmenopausal women who have not undergone estrogen replacement therapy. Raloxifene Hydrochloride 66-90 prolactin Homo sapiens 233-236 12370106-14 2002 CONCLUSIONS: The decrease of PRL values induced by long-term raloxifene administration in postmenopausal women could be explained by a direct antiestrogenic effect of raloxifene on lactotrope cells or by the recently suggested increase of opiatergic tone on the hypothalamic-pituitary region. Raloxifene Hydrochloride 61-71 prolactin Homo sapiens 29-32 12370106-14 2002 CONCLUSIONS: The decrease of PRL values induced by long-term raloxifene administration in postmenopausal women could be explained by a direct antiestrogenic effect of raloxifene on lactotrope cells or by the recently suggested increase of opiatergic tone on the hypothalamic-pituitary region. Raloxifene Hydrochloride 167-177 prolactin Homo sapiens 29-32 30865525-0 2019 THE EFFECT OF RALOXIFENE ON SERUM PROLACTIN LEVEL IN PATIENTS WITH PROLACTINOMA. Raloxifene Hydrochloride 14-24 prolactin Homo sapiens 34-43 30865525-1 2019 Objective: To evaluate the effect of raloxifene on prolactin (PRL) levels in addition to dopamine agonist (DA) therapy in patients with prolactinoma. Raloxifene Hydrochloride 37-47 prolactin Homo sapiens 51-60 30865525-1 2019 Objective: To evaluate the effect of raloxifene on prolactin (PRL) levels in addition to dopamine agonist (DA) therapy in patients with prolactinoma. Raloxifene Hydrochloride 37-47 prolactin Homo sapiens 62-65 30865525-4 2019 PRL level was measured at 1 to 6 months after starting raloxifene and at 1 to 3 months following its discontinuation. Raloxifene Hydrochloride 55-65 prolactin Homo sapiens 0-3 30865525-5 2019 Raloxifene was stopped in 8 out of 14 patients after 2 (1 to 6) months of treatment as the absolute change in PRL level was felt to be small. Raloxifene Hydrochloride 0-10 prolactin Homo sapiens 110-113 30865525-8 2019 Ten patients had an absolute and percentage decrease in PRL of 8.3 ng/mL (1.5 to 54.2 ng/mL) and 25.9% (8 to 55%) from baseline, respectively, after 1 to 6 months on raloxifene treatment. Raloxifene Hydrochloride 166-176 prolactin Homo sapiens 56-59 30865525-11 2019 Conclusion: Raloxifene was associated with a 25.9% (8 to 55%) decrease in PRL level in 10/14 (71%) patients with prolactinoma who were on stable doses of DA including 2 patients (14%) who achieved normoprolactinemia. Raloxifene Hydrochloride 12-22 prolactin Homo sapiens 74-77